0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adhera Therapeutics
Its shares trade under the ticker ATRX. It has been listed since 15 April 1994. In the fiscal year to 31 December 2020, it reported revenue of $132,000 and a net loss of $3.8m. At that date it held total assets of $1,000 and shareholders' equity of −$14.8m.
Adhera Therapeutics, Inc. engages in the discovery, development, and commercialization of drug therapeutics for hypertension. The company is headquartered in Wake Forest, North Carolina. The firm develops and commercializes pharmaceutical therapies and provides technology to improve patient outcomes. The company is also focused on developing and commercializing late-stage, non-addictive pain therapeutics. The company provides Celecoxib-Lisinopril fixed dose combination (IT-102) and Celecoxib-Olmesartan fixed dose combination (IT-103), which are designed to control the side-effect of edema that prohibits the drug from being prescribed at higher doses. IT-102 targets a population requiring angiotensin converting enzyme (ACE) inhibitors, such as lisinopril and IT-103 targets a population requiring olmesartan. The firm is also focused on commercializing perindopril arginine and amlodipine besylate (PRESTALIA) through DyrctAxess, which is a patient-centric treatment platform.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Apr 1994
- Employees
- 1
- Website
- adherathera.com ↗
Leadership
Pay as last reported
- Mr. Andrew KucharchukVice Chairman of the Board, Acting Chief Financial Officer, Chief Operating Officer, Chief Business Officer, since 2020$285,000
- Mr. Charles RiceIndependent Director$24,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adhera Therapeutics develops Celecoxib-Lisinopril fixed dose combination IT-102 for hypertension treatment.
- The company focuses on non-addictive pain therapeutics in late-stage development.
- Adhera commercializes PRESTALIA through DyrctAxess patient-centric platform.
Weaknesses
- Adhera employs only one full-time employee in Wake Forest, North Carolina.
- The company has no listed competitors in the hypertension drug market.
- Adhera's business is limited to two fixed dose combinations IT-102 and IT-103.
Opportunities
- Adhera can expand IT-102 and IT-103 to target ACE inhibitor populations in the US.
- The company may leverage DyrctAxess to commercialize PRESTALIA in new markets.
- Adhera could develop additional non-addictive pain therapeutics for broader use.
Threats
- Adhera faces limited market reach due to a single employee and small operations.
- The company's reliance on fixed dose combinations may face regulatory challenges.
- Adhera's late-stage pain therapeutics could encounter competition from larger firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.